40 Dalton Street,

Boston,

MA,

US,

ZIP: 02115

Phone: +4402031418700

Following the FDA’s announcement of ‘Alternative Methods Working Group’ in the summer, 2021, Roche’s newly opened pRED Innovation Center in Basel, and exciting data from Recce Pharma’s anti-infective candidate using organoids, the 7th Annual 3D Tissue Models Summit will return to Boston in May 2022 to reunite the community of drug discovery and development experts. This is the definitive meeting for drug developers to explore and integrate complex 3D models featuring 30+ real-life case studies across 2 dedicated tracks and their lessons learned.

Join us in May to stay ahead of the curve and through 30+ real-life case studies, you will learn and meet trailblazers in 3D models to revolutionize your drug discovery and development protocols, giving you greater confidence in clinical relevancy and accelerating novel treatments to patients in a safe and affordable manner!

Tickets    https://go.evvnt.com/1014402-1?pid=1052
Brochure https://go.evvnt.com/1014402-3?pid=1052

Prices:
Conference Only - Biopharma Pricing USD 1699.00
Conference + 1 Workshop - Biopharma Pricing USD 1948.00
Conference + 2 Workshops - Biopharma Pricing USD 2197.00
Conference Only - Academic Pricing USD 2199.00
Conference + 1 Workshop - Academic Pricing USD 2548.00
Conference + 2 Workshops - Academic Pricing USD 1797.00
Conference Only - Solution Provider Pricing USD 3599.00
Conference + 1 Workshop - Solution Provider Pricing USD 4198.00
Conference + 2 Workshops - Solution Provider  USD 4797.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development

Philip Hewitt, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA, Beth Hoffmann, Founder & CEO, Origami Therapeutics, Timothy Spicer, Senior Scientific Director-Dept. of Molecular Medicine, Scripps Research, Andrew Thorley, Principal Scientist Group Leader - OMNI Biomarker Development, Genentech, Dennis Plenker, Senior Scientist, LOXO Oncology at Lilly, Kenneth Pryde, Senior Scientist, Oncology Safety Sciences, AstraZeneca, Kimberly Homan, Director, Complex in vitro Systems group, Genentech, Valeria Chichagova, Associate Director and Head of iPSC Technology, Newcells Biotech, Patrick Devine, Principal Senior Scientist, Novartis, Sandra J. Engle, Senior Director, Head of Translational Cell Sciences, Biogen, Suzanne Fitzpatrick, Senior Advisor for Toxicology, FDA, Esmaiel Jabbari, Professor of Chemical & Biomedical Engineering, University of South Carolina, Min Jae Song, Staff Scientist, NCATS/NIH, Richard Visconti, Director of Preclinical Pharmacology & Toxicology, Legend Biotech, Juan Patarroyo, Principal Scientist I, Novartis, Piyush Bajaj, Senior Principal Scientist, Sanofi, Richard Hanna, Associate Director Bioscience Immunology, AstraZeneca, Andrew Burdick, Director – Investigative Toxicology, Pfizer, John Wikswo, Professor, Vanderbilt University, Prashanth Gokare, Scientist Discovery Biology (3D Organoid Platform Lead), Janssen, Danilo A. Tagle Director, Office of Special Initiatives, National Center for Advancing Translational Sciences National Institutes of Health, Dr. Jamie L. Harden, Director – Research, Evommune, Inc, Prathap Kumar Mahalingaiah, Principal Research ScientistInvestigative Toxicology & Pathology, AbbVie, Katrina Wisdom, Investigator, Bioengineer in Complex In Vitro Models, GSK, Ratnakar Potla, Senior Scientist, Genentech, Scott MacDonnell, Associate Director Cardiovascular, Fibrosis & Renal Research, Regeneron Pharmaceuticals, Abhinav Sharma, Abhinav Sharma Postdoctoral Research Scientist, AbbVie, Daniel Harrington, Assistant Professor, The University of Texas Health Science Center at Houston (UTHealth), Megan LaFollette, Program Manager, The North American 3 Rs Collaborative, Nicholas Geisse, Chief Science Officer, Curi Bio, Sumeer Dhar, Global Head Scientific Sales & Marketing Bioscience & Pharmaceuticals, SCREEN GP EUROPE B.V., Yixiao Cui, Postdoctoral Fellow, Immunology & Respiratory, Boehringer Ingelheim